Raltegravir in HIV-1–Infected pregnant women: pharmacokinetics, safety, and efficacy
MI Blonk, APH Colbers… - Clinical infectious …, 2015 - academic.oup.com
Background. The use of raltegravir in human immunodeficiency virus (HIV)–infected
pregnant women is important in the prevention of mother-to-child HIV transmission …
pregnant women is important in the prevention of mother-to-child HIV transmission …
[引用][C] Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy
MI Blonk, APH Colbers, C Hidalgo-Tenorio… - Clinical Infectious …, 2015 - cir.nii.ac.jp
Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
[PDF][PDF] Raltegravir in HIV-1 Infected Pregnant Women: Pharmacokinetics, Safety and Efficacy
M Blonk, A Colbers, C Hidalgo-Tenorio, K Kabeya… - 2015 - natap.org
Methods An open-label, multi-centre, phase IV study in HIV-infected pregnant women
receiving raltegravir 400 mg twice daily, was performed (PANNA Network). Steady state …
receiving raltegravir 400 mg twice daily, was performed (PANNA Network). Steady state …
[PDF][PDF] Raltegravir in HIV-1 Infected Pregnant Women: Pharmacokinetics, Safety and Efficacy
M Blonk, A Colbers, C Hidalgo-Tenorio… - … to antiretroviral agents …, 2015 - repository.ubn.ru.nl
Background: The use of raltegravir in HIV-infected pregnant women is important in the
prevention of mother-to-child HIV transmission (MTCT), especially in circumstances when a …
prevention of mother-to-child HIV transmission (MTCT), especially in circumstances when a …
Raltegravir in HIV-1-infected pregnant women: Pharmacokinetics, safety, and efficacy
M Blonk, A Colbers, C Hidalgo-Tenorio… - Clinical Infectious …, 2015 - repub.eur.nl
Background. The use of raltegravir in human immunodeficiency virus (HIV)-infected
pregnant women is important in the prevention of mother-to-child HIV transmission …
pregnant women is important in the prevention of mother-to-child HIV transmission …
Raltegravir in HIV-1-infected pregnant women: pharmacokinetics, safety, and efficacy.
MI Blonk, APH Colbers, C Hidalgo-Tenorio, K Kabeya… - 2015 - cabidigitallibrary.org
Background. The use of raltegravir in human immunodeficiency virus (HIV)-infected
pregnant women is important in the prevention of mother-to-child HIV transmission …
pregnant women is important in the prevention of mother-to-child HIV transmission …
[引用][C] Raltegravir in HIV-1-infected pregnant women: Pharmacokinetics, safety, and efficacy
MMI Blonk, A Gingelmaier, G Taylor… - Clinical infectious …, 2015 - difusion.ulb.ac.be
[PDF][PDF] Raltegravir in HIV-1 Infected Pregnant Women: Pharmacokinetics, Safety and Efficacy
M Blonk, A Colbers, C Hidalgo-Tenorio… - … not too much–not too little, 2015 - core.ac.uk
Background: The use of raltegravir in HIV-infected pregnant women is important in the
prevention of mother-to-child HIV transmission (MTCT), especially in circumstances when a …
prevention of mother-to-child HIV transmission (MTCT), especially in circumstances when a …
[PDF][PDF] Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy
MI Blonk, APH Colbers, C Hidalgo-Tenorio… - Clinical Infectious …, 2015 - researchgate.net
Background. The use of raltegravir in human immunodeficiency virus (HIV)–infected
pregnant women is important in the prevention of mother-to-child HIV transmission …
pregnant women is important in the prevention of mother-to-child HIV transmission …
[引用][C] Raltegravir in HIV-1-infected pregnant women: Pharmacokinetics, safety, and efficacy
MI Blonk, APH Colbers, C Hidalgo Tenorio… - CLINICAL …, 2015 - research.unipd.it